/PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of...

Related Keywords

Germany , New York , United States , Netherlands , United Kingdom , New York University , Singapore , Switzerland , London , City Of , Dutch , Swiss , Bertrand Damour , Danny Reinberg , Michael Gladstone , Minerva Neurosciences , Shaun Kirkpatrick , David Thurston , Leigh Zawel , Rogier Rooswinkel , Jonathan Tobin , Paul Jackson , Geneprot Inc , Novartis Institutes For Biomedical Research , Biotechnologies At Research Corporation Technologies , Boehringer Ingelheim , European Recovery Programme , Merck Co , Rabobank International , Deutsche Bank , Jp Morgan , Taiho Pharmaceuticals , Atlas Venture , York University School Of Medicine , Company Board , Dutch Venture Initiative , Research Corporation Technologies , Brandon Capital , Chief Executive , Chief Scientific , Antibody Drug Conjugate , Executive Officer Bertrand Damour , Professor David , Professor Thurston , Chief Executive Officer , Pheon Therapeutics , Cullinan Oncology , Vice President , East Coast Site Head , Therapeutic Innovation , Oncology Site Head , Novartis Institutes , Biomedical Research , Molecular Pharmacology , New York University School , Chief Scientific Officer , Chair Jonathan Tobin , General Partner , President Biotechnologies , Brandon Biocatalyst , United Nations Principles , Kfw Capital , Venture Capital Fonds , Health Care Amp Hospitals , Medical Pharmaceuticals , Biotechnology , Pharmaceuticals , Personnel Announcements , Venture Capital ,